These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 10965223

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells.
    Lugnier C, Schini VB.
    Biochem Pharmacol; 1990 Jan 01; 39(1):75-84. PubMed ID: 2153383
    [Abstract] [Full Text] [Related]

  • 4. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis.
    Netherton SJ, Maurice DH.
    Mol Pharmacol; 2005 Jan 01; 67(1):263-72. PubMed ID: 15475573
    [Abstract] [Full Text] [Related]

  • 5. Altered expression of cyclic nucleotide phosphodiesterase isozymes during culture of aortic endothelial cells.
    Ashikaga T, Strada SJ, Thompson WJ.
    Biochem Pharmacol; 1997 Nov 15; 54(10):1071-9. PubMed ID: 9464449
    [Abstract] [Full Text] [Related]

  • 6. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus.
    Suvarna NU, O'Donnell JM.
    J Pharmacol Exp Ther; 2002 Jul 15; 302(1):249-56. PubMed ID: 12065724
    [Abstract] [Full Text] [Related]

  • 7. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
    Ko WC, Shih CM, Lai YH, Chen JH, Huang HL.
    Biochem Pharmacol; 2004 Nov 15; 68(10):2087-94. PubMed ID: 15476679
    [Abstract] [Full Text] [Related]

  • 8. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram.
    Michie AM, Lobban M, Müller T, Harnett MM, Houslay MD.
    Cell Signal; 1996 Feb 15; 8(2):97-110. PubMed ID: 8730511
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Characterisation of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery.
    Pauvert O, Salvail D, Rousseau E, Lugnier C, Marthan R, Savineau JP.
    Biochem Pharmacol; 2002 May 01; 63(9):1763-72. PubMed ID: 12007579
    [Abstract] [Full Text] [Related]

  • 12. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
    Ahlström M, Pekkinen M, Huttunen M, Lamberg-Allardt C.
    Cell Mol Biol Lett; 2005 May 01; 10(2):305-19. PubMed ID: 16010295
    [Abstract] [Full Text] [Related]

  • 13. Phosphodiesterases do not limit beta1-adrenoceptor-mediated sinoatrial tachycardia: evidence with PDE3 and PDE4 in rabbits and PDE1-5 in rats.
    Kaumann AJ, Galindo-Tovar A, Escudero E, Vargas ML.
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Nov 01; 380(5):421-30. PubMed ID: 19693491
    [Abstract] [Full Text] [Related]

  • 14. VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors.
    Favot L, Keravis T, Holl V, Le Bec A, Lugnier C.
    Thromb Haemost; 2003 Aug 01; 90(2):334-43. PubMed ID: 12888882
    [Abstract] [Full Text] [Related]

  • 15. Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium.
    Hambleton R, Krall J, Tikishvili E, Honeggar M, Ahmad F, Manganiello VC, Movsesian MA.
    J Biol Chem; 2005 Nov 25; 280(47):39168-74. PubMed ID: 16172121
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant.
    Erdogan S, Houslay MD.
    Biochem J; 1997 Jan 01; 321 ( Pt 1)(Pt 1):165-75. PubMed ID: 9003416
    [Abstract] [Full Text] [Related]

  • 18. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.
    Verde I, Vandecasteele G, Lezoualc'h F, Fischmeister R.
    Br J Pharmacol; 1999 May 01; 127(1):65-74. PubMed ID: 10369457
    [Abstract] [Full Text] [Related]

  • 19. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells.
    Verghese MW, McConnell RT, Lenhard JM, Hamacher L, Jin SL.
    Mol Pharmacol; 1995 Jun 01; 47(6):1164-71. PubMed ID: 7603456
    [Abstract] [Full Text] [Related]

  • 20. Endothelium-independent and endothelium-dependent vasorelaxation by a dichloromethane fraction from Anogeissus Leiocarpus (DC) Guill. Et Perr. (Combretaceae): possible involvement of cyclic nucleotide phosphodiesterase inhibition.
    Belemnaba L, Ouédraogo S, Auger C, Chataigneau T, Traore A, Guissou IP, Lugnier C, Schini-Kerth VB, Bucher B.
    Afr J Tradit Complement Altern Med; 2013 Jun 01; 10(2):173-9. PubMed ID: 24146440
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.